BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed VTRS catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:6a90fda403a7b2c6b67e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:VTRS P3 readout (est.): OPUS-2
DESCRIPTION:A Research Study to Evaluate the Efficacy and Safety of Cenerim
 od in Subjects Suffering From Systemic Lupus Erythematosus\nNCT05672576 | 
 PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Viatris Innovation GmbH\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nTic
 ker VTRS (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT056
 72576\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05672576
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:8db5b91c7c809d3ad167@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260729
SUMMARY:VTRS APPROVAL: GWYN LO
DESCRIPTION:Approved 2026-07-28: GWYN LO (NDA219990 ORIG1)\nConfidence: con
 firmed\nTicker VTRS (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219990\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219990
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
